ARS Pharmaceuticals Inc
NASDAQ:SPRY
Cash Flow Statement
Cash Flow Statement
ARS Pharmaceuticals Inc
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||||||||||
| Net Income |
(27)
|
(33)
|
(47)
|
(71)
|
(79)
|
(89)
|
(95)
|
(90)
|
(85)
|
(35)
|
(25)
|
(23)
|
(20)
|
(54)
|
(50)
|
(45)
|
(49)
|
8
|
(16)
|
(48)
|
(80)
|
|
| Depreciation & Amortization |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Stock-Based Compensation |
0
|
4
|
8
|
13
|
18
|
3
|
3
|
4
|
4
|
6
|
3
|
0
|
(2)
|
9
|
10
|
12
|
13
|
15
|
17
|
19
|
21
|
|
| Other Non-Cash Items |
2
|
4
|
8
|
13
|
17
|
20
|
21
|
21
|
22
|
7
|
2
|
(3)
|
(7)
|
2
|
3
|
4
|
5
|
7
|
9
|
14
|
17
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
(1)
|
(3)
|
2
|
7
|
4
|
2
|
(1)
|
(7)
|
(10)
|
(13)
|
(10)
|
(8)
|
(3)
|
(7)
|
(7)
|
(4)
|
(2)
|
(2)
|
(14)
|
(19)
|
(23)
|
|
| Cash from Operating Activities |
(26)
N/A
|
(31)
-20%
|
(36)
-15%
|
(50)
-40%
|
(57)
-13%
|
(67)
-18%
|
(74)
-11%
|
(75)
-1%
|
(73)
+3%
|
(40)
+45%
|
(33)
+18%
|
(34)
-5%
|
(30)
+11%
|
(59)
-95%
|
(54)
+10%
|
(44)
+18%
|
(46)
-4%
|
14
N/A
|
(20)
N/A
|
(53)
-158%
|
(85)
-62%
|
|
| Investing Cash Flow | ||||||||||||||||||||||
| Capital Expenditures |
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(0)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Other Items |
0
|
0
|
0
|
0
|
(40)
|
(65)
|
0
|
0
|
(25)
|
0
|
(111)
|
(66)
|
(113)
|
(87)
|
16
|
(42)
|
22
|
(106)
|
(68)
|
(7)
|
(68)
|
|
| Cash from Investing Activities |
(1)
N/A
|
(1)
-37%
|
(1)
-1%
|
(2)
-75%
|
(41)
-2 418%
|
(66)
-62%
|
(67)
0%
|
(66)
+1%
|
(26)
+60%
|
(0)
+99%
|
(111)
-55 610%
|
(66)
+41%
|
(113)
-70%
|
(87)
+23%
|
16
N/A
|
(42)
N/A
|
22
N/A
|
(106)
N/A
|
(69)
+35%
|
(7)
+89%
|
(69)
-846%
|
|
| Financing Cash Flow | ||||||||||||||||||||||
| Net Issuance of Common Stock |
154
|
412
|
390
|
391
|
259
|
1
|
1
|
1
|
2
|
1
|
2
|
5
|
4
|
7
|
6
|
4
|
3
|
3
|
3
|
6
|
5
|
|
| Net Issuance of Debt |
9
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
(9)
|
(9)
|
(9)
|
(9)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
100
|
|
| Other |
0
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
199
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
69
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
163
N/A
|
409
+151%
|
387
-5%
|
387
+0%
|
256
-34%
|
1
-100%
|
1
+25%
|
1
-24%
|
2
+178%
|
191
+11 747%
|
192
+1%
|
195
+1%
|
194
0%
|
7
-96%
|
6
-15%
|
4
-39%
|
3
-7%
|
72
+2 099%
|
73
+1%
|
75
+3%
|
174
+132%
|
|
| Change in Cash | ||||||||||||||||||||||
| Net Change in Cash |
136
N/A
|
376
+177%
|
350
-7%
|
336
-4%
|
158
-53%
|
(133)
N/A
|
(140)
-6%
|
(141)
-1%
|
(98)
+31%
|
150
N/A
|
48
-68%
|
94
+97%
|
51
-46%
|
(140)
N/A
|
(32)
+77%
|
(82)
-159%
|
(21)
+75%
|
(20)
+3%
|
(16)
+20%
|
15
N/A
|
20
+33%
|
|
| Free Cash Flow | ||||||||||||||||||||||
| Free Cash Flow |
(27)
N/A
|
(32)
-20%
|
(37)
-14%
|
(52)
-40%
|
(58)
-12%
|
(68)
-18%
|
(76)
-11%
|
(77)
-1%
|
(74)
+3%
|
(40)
+46%
|
(33)
+18%
|
(34)
-4%
|
(30)
+11%
|
(59)
-96%
|
(54)
+10%
|
(44)
+18%
|
(46)
-4%
|
13
N/A
|
(21)
N/A
|
(53)
-154%
|
(86)
-61%
|
|